Results 21 to 30 of about 4,861,637 (146)

Ablative radiotherapy in castration-resistant prostate cancer. [PDF]

BJU Int
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC.   +9 more
europepmc   +2 more sources

Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Clinical and Translational Radiation Oncology, 2022
Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in ...
Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy   +14 more
doaj   +1 more source

The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas

Nowotwory, 2023
Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach.
Konrad Zasadziński, Mateusz J. Spałek
doaj   +1 more source

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy

Thoracic Cancer, 2022
Highly active and durable systemic therapies such as targeted therapy and immunotherapy can convert widespread metastatic disease into oligometastatic status, for which metastasis‐directed local intervention can control and potentially prolong survival ...
Ho Young Lee, Sung Hyun Kim, Hong Yeul Lee, Young‐Min Lee, Ji Yeon Han, Heunglae Cho, Hyun‐Kyung Lee   +6 more
doaj   +1 more source

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review

Frontiers in Oncology, 2022
Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of ...
Alexander Yaney, Andrew Stevens, Paul Monk, Douglas Martin, Dayssy A. Diaz, Shang-Jui Wang   +5 more
doaj   +1 more source

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Diagnostics, 2023
Stereotactic ablative radiotherapy (SABR) may improve survival in patients with inoperable pulmonary oligometastases. However, the impact of pulmonary oligometastatic status after systemic therapy on SABR outcomes remains unclear.
Chin-Beng Ho, Jo-Ting Tsai, Chun-You Chen, Her-Shyong Shiah, Hsuan-Yu Chen, Lai-Lei Ting, Chia-Chun Kuo, I-Chun Lai, Hsin-Yi Lai, Chi-Li Chung, Kai-Ling Lee, Huey-En Tzeng, Kuen-Haur Lee, Hsin-Lun Lee, Shang-Wen Chen, Jeng-Fong Chiou   +15 more
doaj   +1 more source

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. [PDF]

Thorac Cancer
Serial re‐biopsy in EGFR‐mutant NSCLC revealed sequential acquired EGFR T790M, MET c.3010C>G exon 14‐related alteration, and RET‐CCDC6 fusion. Mechanism‐guided therapy with almonertinib, almonertinib plus savolitinib, and later selpercatinib plus almonertinib with local radiotherapy achieved prolonged disease control, with survival approaching 50 ...
Zhu Y, Wang C, Hu NL, Wang DH, Wu SK.
europepmc   +2 more sources

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions

Advances in Radiation Oncology, 2022
Purpose: Given the relative radioresistance of sarcomas and their often large size, conventional palliative radiation therapy (RT) often offers limited tumor control and symptom relief.
David Boyce-Fappiano, MD, MHM, Ethan P. Damron, BS, Ahsan Farooqi, MD, PhD, Devarati Mitra, MD, PhD, Anthony P. Conley, MD, Neeta Somaiah, MD, Dejka M. Araujo, MD, J. Andrew Livingston, MD, Ravin Ratan, MD, MEd, Emily Z. Keung, MD, Christina L. Roland, MD, MS, B. Ashleigh Guadagnolo, MD, MPH, Andrew J. Bishop, MD   +12 more
doaj   +1 more source

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Case Reports in Oncology, 2020
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC).
David König, Urs R. Meier, Bernd Klaeser, Spasenija Savic, Miklos Pless   +4 more
doaj   +1 more source

Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience

Frontiers in Oncology, 2022
ObjectivesTo investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.MethodsSingle-institution retrospective analysis of 60 NSCLC ...
Leah M. Katz, Victor Ng, S. Peter Wu, Sherry Yan, David Grew, Samuel Shin, Nicholas W. Colangelo, Allison McCarthy, Harvey I. Pass, Abraham Chachoua, Peter B. Schiff   +10 more
doaj   +1 more source